


01/2008:1597 *Limits:***TRAMAZOLINE HYDROCHLORIDE  
MONOHYDRATE**

Tramazolini hydrochloridum monohydricum

C<sub>13</sub>H<sub>18</sub>ClN<sub>3</sub>·H<sub>2</sub>O  
[74195-73-6]M<sub>r</sub> 269.8**DEFINITION***N*-(5,6,7,8-Tetrahydronaphthalen-1-yl)-4,5-dihydro-1*H*-imidazol-2-amine hydrochloride monohydrate.*Content:* 98.5 per cent to 101.5 per cent (anhydrous substance).**CHARACTERS***Appearance:* white or almost white, crystalline powder.*Solubility:* soluble in water and in ethanol (96 per cent).**IDENTIFICATION**

A. Infrared absorption spectrophotometry (2.2.24).

*Comparison:* tramazoline hydrochloride monohydrate CRS.



B. It gives reaction (a) of chlorides (2.3.1).

**TESTS****Solution S.** Dissolve 2.5 g in carbon dioxide-free water *R* and dilute to 50 mL with the same solvent.**Appearance of solution.** Solution S is clear (2.2.1) and not more intensely coloured than reference solution Y<sub>6</sub> (2.2.2, Method II).**pH** (2.2.3): 4.9 to 6.3 for solution S.**Related substances.** Liquid chromatography (2.2.29).*Test solution.* Dissolve 50.0 mg of the substance to be examined in a mixture of 50 volumes of acetonitrile *R* and 50 volumes of water *R* and dilute to 50.0 mL with the same mixture of solvents.*Reference solution (a).* Dissolve 5.0 mg of tramazoline impurity A CRS and 5.0 mg of tramazoline impurity B CRS in 5 mL of a mixture of 50 volumes of acetonitrile *R* and 50 volumes of water *R* and add 5 mL of the test solution.*Reference solution (b).* Dilute 0.2 mL of reference solution (a) to 100 mL with a mixture of 50 volumes of acetonitrile *R* and 50 volumes of water *R*.*Column:*


- *size:* *l* = 0.125 m, Ø = 4 mm,
- *stationary phase:* octadecylsilyl silica gel for chromatography *R* (5 µm).

*Mobile phase:* 2.0 g/L solution of sodium dodecyl sulfate *R* in a mixture of 6 volumes of 2-propanol *R*, 42 volumes of acetonitrile *R* and 52 volumes of water *R*.*Flow rate:* 1.2 mL/min.*Detection:* spectrophotometer at 215 nm.*Injection:* 5 µL.*Run time:* 3 times the retention time of tramazoline.*Relative retention* with reference to tramazoline (retention time = about 6.5 min): impurity A = about 0.71; impurity B = about 0.86.*System suitability:* reference solution (a):

- the chromatogram obtained shows 3 clearly separated peaks,
- *resolution:* minimum 1.5 between tramazoline and impurity B.

– *impurity A:* not more than 3 times the area of the corresponding peak in the chromatogram obtained with reference solution (b) (0.3 per cent),– *impurity B:* not more than 3 times the area of the corresponding peak in the chromatogram obtained with reference solution (b) (0.3 per cent),– *any other impurity:* not more than the area of the peak due to impurity B in the chromatogram obtained with reference solution (b) (0.1 per cent),– *sum of other impurities:* not more than twice the area of the peak due to impurity B in the chromatogram obtained with reference solution (b) (0.2 per cent),– *disregard limit:* 0.2 times the area of the peak due to impurity B in the chromatogram obtained with reference solution (b) (0.02 per cent).**Water** (2.5.12): 6.2 per cent to 7.2 per cent, determined on 0.500 g.**Sulfated ash** (2.4.14): maximum 0.1 per cent, determined on 1.0 g.**ASSAY**Dissolve 2.000 g in a mixture of 5 mL of 0.1 *M* hydrochloric acid and 75 mL of ethanol (96 per cent) *R*. Carry out a potentiometric titration (2.2.20) using 1 *M* sodium hydroxide. Read the volume added between the 2 points of inflexion.1 mL of 1 *M* sodium hydroxide is equivalent to 251.8 mg of C<sub>13</sub>H<sub>18</sub>ClN<sub>3</sub>.**IMPURITIES**A. *N*-(naphthalen-1-yl)-4,5-dihydro-1*H*-imidazol-2-amine,B. mixture of 1-acetyl-*N*-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1*H*-imidazol-2-amine and 1-[(*EZ*)-1-[(5,6,7,8-tetrahydronaphthalen-1-yl)imino]ethyl]imidazolidin-2-one.01/2008:2245  
corrected 7.0**TRANDOLAPRIL**

Trandolaprilum

C<sub>24</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub>  
[87679-37-6]M<sub>r</sub> 430.5**DEFINITION**(2*S*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid.*Content:* 99.0 per cent to 101.0 per cent (anhydrous substance).

## CHARACTERS

*Appearance*: white or almost white powder.

*Solubility*: practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in anhydrous ethanol.

## IDENTIFICATION

A. Specific optical rotation (see Tests).

B. Infrared absorption spectrophotometry (2.2.24).

*Comparison*: trandolapril CRS.

## TESTS

**Appearance of solution.** The solution is not more intensely coloured than reference solution Y<sub>7</sub> (2.2.2, Method II).

Dissolve 1.0 g in *methanol R* and dilute to 10 mL with the same solvent.

**Specific optical rotation** (2.2.7): – 16.5 to – 18.5 (anhydrous substance).

Dissolve 1.0 g in *anhydrous ethanol R* and dilute to 50.0 mL with the same solvent.

**Related substances.** Liquid chromatography (2.2.29).

*Test solution.* Dissolve 25.0 mg of the substance to be examined in mobile phase A and dilute to 10.0 mL with mobile phase A.

*Reference solution (a).* Dilute 1.0 mL of the test solution to 10.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 100.0 mL with mobile phase A.

*Reference solution (b).* Dissolve 5 mg of *trandolapril impurity C CRS* and 5 mg of *trandolapril impurity D CRS* in mobile phase A and dilute to 5 mL with mobile phase A. Dilute 1 mL of this solution to 20 mL with mobile phase A.

*Column*:

- *size*:  $l = 0.15$  m,  $\varnothing = 4.6$  mm,
- *stationary phase*: end-capped polar-embedded octadecylsilyl amorphous organosilica polymer R (3.5  $\mu$ m),
- *temperature*: 40 °C.

*Mobile phase*:

- *mobile phase A*: mix 25 volumes of *acetonitrile R*, and 75 volumes of a 6.8 g/L solution of *potassium dihydrogen phosphate R* previously adjusted to pH  $2.5 \pm 0.1$  with *phosphoric acid R*;
- *mobile phase B*: mix equal volumes of *acetonitrile R*, and a 6.8 g/L solution of *potassium dihydrogen phosphate R* previously adjusted to pH  $2.2 \pm 0.1$  with *phosphoric acid R*;

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 20	95	5
20 - 35	95 → 5	5 → 95
35 - 45	5	95

*Flow rate*: 1.3 mL/min.

*Detection*: spectrophotometer at 210 nm.

*Injection*: 20  $\mu$ L.

*Relative retention* with reference to trandolapril (retention time = about 14.5 min): impurity C = about 2.1; impurity D = about 2.5.

*System suitability*: reference solution (b):

- *resolution*: minimum 4 between the peaks due to impurity C and impurity D.

*Limits*:

- *correction factor*: for the calculation of content, multiply the peak area of impurity C by 2.2,
- *impurity C*: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent),
- *impurity D*: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent),
- *unspecified impurities*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent),
- *sum of impurities other than D*: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent),
- *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

**Palladium**: maximum 5 ppm.

Atomic absorption spectrometry (2.2.23, Method I).

*Solvent mixture*: *nitric acid R*, *water R* (1:99 V/V).

*Test solution.* To the residue of the test for sulfated ash add 3 mL of *hydrochloric acid R* and 1 mL of *fuming nitric acid R*. Cover the crucible with a watch glass and heat at 160-170 °C for 1 h to dissolve the residue. Afterwards continue heating in the open crucible and evaporate the solution. Stop heating before the residue is completely dried, add 1 mL of *nitric acid R*, heat at 160-170 °C for further 10 min, and after cooling dilute to 10.0 mL with *water R*.

*Reference solutions.* Prepare reference solutions containing 0.5  $\mu$ g, 1.0  $\mu$ g and 1.5  $\mu$ g of Pd per millilitre by diluting *palladium standard solution (500 ppm Pd) R* with the solvent mixture.

*Source*: palladium hollow-cathode lamp.

*Wavelength*: 244.8 nm.

*Atomisation device*: air-acetylene flame.

**Water** (2.5.32): maximum 0.2 per cent, determined on 1.000 g.

**Sulfated ash** (2.4.14): maximum 0.1 per cent, determined on 2.0 g in a porcelain or quartz crucible.

## ASSAY

Dissolve 0.300 g in 50 mL of *anhydrous acetic acid R*. Titrate with 0.1 M *perchloric acid*, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M *perchloric acid* is equivalent to 43.05 mg of C<sub>24</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub>.


## STORAGE

Protected from light.


## IMPURITIES

*Specified impurities*: C, D.


*Other detectable impurities* (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): A, B, E, F.




- A. R = CH<sub>3</sub>: (2*S*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-1-(methoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid (methyl ester derivative),
- B. R = CH(CH<sub>3</sub>)<sub>2</sub>: (2*S*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-1-[(1-methylethoxy)carbonyl]-3-phenylpropyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid (isopropyl ester derivative),
- E. R = H: (2*S*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-1-carboxy-3-phenylpropyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid (trandolaprilate),



- C. (2*S*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid (hexahydrotrandolapril),



- D. ethyl (2*S*)-2-[(3*S*,5*aS*,9*aR*,10*aS*)-3-methyl-1,4-dioxodecahydropyrazino[1,2-*a*]indol-2(1*H*)-yl]-4-phenylbutanoate (trandolapril diketopiperazine),




- F. (2*R*,3*aR*,7*aS*)-1-[(2*S*)-2-[[1*S*]-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydro-1*H*-indole-2-carboxylic acid.

01/2008:0875  
corrected 6.0

## TRANEXAMIC ACID

### Acidum tranexamicum



C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub>  
[1197-18-8]

M<sub>r</sub> 157.2

#### DEFINITION

*trans*-4-(Aminomethyl)cyclohexanecarboxylic acid.

*Content*: 99.0 per cent to 101.0 per cent (dried substance).

#### CHARACTERS

*Appearance*: white or almost white, crystalline powder.

*Solubility*: freely soluble in water and in glacial acetic acid, practically insoluble in acetone and in ethanol (96 per cent).

#### IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

*Preparation*: discs.

*Comparison*: tranexamic acid CRS.

#### TESTS

**pH** (2.2.3): 7.0 to 8.0.

Dissolve 2.5 g in *carbon dioxide-free water R* and dilute to 50 mL with the same solvent.

**Related substances**. Liquid chromatography (2.2.29).

*Test solution*. Dissolve 0.20 g of the substance to be examined in *water R* and dilute to 20.0 mL with the same solvent.

*Reference solution (a)*. Dilute 5.0 mL of the test solution to 100.0 mL with *water R*. Dilute 1.0 mL of this solution to 10.0 mL with *water R*.

*Reference solution (b)*. Dissolve 20 mg of *tranexamic acid CRS* (containing impurity C) in *water R* and dilute to 2 mL with the same solvent.

*Reference solution (c)*. Dissolve 12 mg of *4-aminomethylbenzoic acid R* (impurity D) in *water R* and dilute to 100 mL with the same solvent. Dilute 1 mL of the solution to 50 mL with *water R*. Dilute 5 mL of this solution to 200 mL with *water R*.

*Column*:

- *size*: *l* = 0.25 m, Ø = 4.6 mm or *l* = 0.25 m, Ø = 6.0 mm;
- *stationary phase*: octadecylsilyl silica gel for chromatography R (5 µm).

*Mobile phase*: dissolve 11.0 g of *anhydrous sodium dihydrogen phosphate R* in 500 mL of *water R* and add 5 mL of *triethylamine R* and 1.4 g of *sodium laurilsulfate R*. Adjust to pH 2.5 with *dilute phosphoric acid R* and dilute to 600 mL with *water R*. Add 400 mL of *methanol R* and mix.

*Flow rate*: 0.9 mL/min.

*Detection*: spectrophotometer at 220 nm.

*Injection*: 20 µL.

*Run time*: 3 times the retention time of tranexamic acid.

*Identification of impurities*: use the chromatogram supplied with *tranexamic acid CRS* and the chromatogram obtained with reference solution (b) to identify the peak due to impurity C; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D.

*Relative retention* with reference to tranexamic acid (retention time = about 13 min): impurity C = about 1.1; impurity D = about 1.3; impurity B = about 1.5; impurity A = about 2.1.

*System suitability*: reference solution (b):

- *resolution*: minimum 1.5 between the peaks due to tranexamic acid and impurity C.

*Limits*:

- *correction factors*: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity B = 1.2; impurity C = 0.005; impurity D = 0.006;
- *impurity A*: not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent);
- *impurity B*: not more than 0.4 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);
- *unspecified impurities*: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- *sum of unspecified impurities*: not more than 0.4 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);
- *disregard limit*: 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.025 per cent).